Conference
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial
Abstract
Abstract
Introduction - Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1). Selinexor with low dose dexamethasone (dex) has demonstrated potent anti-cancer activity in patients with heavily pretreated MM. While the development of proteasome inhibitors (PIs) has transformed the treatment of MM, acquired resistance to PIs limit their efficacy. …
Authors
Bahlis NJ; Kotb R; Sebag M; Sutherland HJ; LeBlanc R; White D; Venner CP; Kouroukis T; Bergstrom D; McCurdy A
Volume
128
Publisher
American Society of Hematology
Publication Date
December 2, 2016
DOI
10.1182/blood.v128.22.977.977
Conference proceedings
Blood
Issue
22
ISSN
0006-4971